Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine for rituximab-failed indolent B-cell lymphoma
CTR20160334Phase 2Suspended
- Sponsor
- Hangzhou Rongli Pharmaceutical Technology
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bendamustine in low-grade B-cell lymphoma, sponsored by Hangzhou Rongli Pharmaceutical Technology. Started Jul 2017; status: suspended.
02
Drugs
bendamustine
03
Conditions
low-grade B-cell lymphoma
Beyond the preview
Go deeper on CTR20160334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160334.